Hummmmmm.If this money raiswed is for the company and not for some white shareholders... this could run. aTyr Pharma closes $86.3M underwritten public offering Sep. 20, 2021 4:32 PM aTyr Pharma(NASDAQ:LIFE) has closed an underwritten public offering of 10,781,250 shares with gross proceeds of $86.3M. Underwriters fully exercised their option to buy an additional 1.4M shares. Piper Sandler and RBC Capital Markets were jint book-runners.
How DBI got it's groove back and maybe a liability.... Designer Brands' Design With Camuto Group, Designer Brands added a lot to their "footprint" in fashion footwear retailing. Specifically, Camuto brought in licenses rights for footwear, and in some cases handbags for prominent and well established brands including those such as Jessica Simpson, Lucky Brand, and through a joint venture, the Jennifer Lopez brand. Designer Brands owns a 40% stake in ABG-Camuto and pays royalties to ABG-Camuto, but with a 40% position, the company receives earnings from ABG-Camuto's royalties received from third parties that license the brands. Camuto Group gives Designer Brands more control in design and sourcing, but the company does not own any manufacturing facilities. Instead, they use third-party manufacturers sourced through their offices in China and Brazil. Their sourcing offices inspect prototypes and oversees suppliers for quality assurance. Direct sourcing of manufacturing also allows for a higher degree of inventory management. All About Brazil! <---- and maybe a hint... Brazil stocks? Supply chains suffering in China maybe they look to Brazil<-----
Atea Pharmaceuticals: Early Stage Developer Of Oral Small Molecule SARS-CoV-2 Therapy Summary Atea has a major deal with Roche. Atea just IPO-ed, but it already has $4.4bn in market cap. The stock is in excellent financial health. Atea Biopharmaceuticals(NASDAQ:AVIR)IPO-ed in October last year at $330mn, issuing 11 million shares. Currently, it has a market cap of $4.4bn and has 84 million outstanding shares. The company’s lead candidate AT-527 is running a phase 3 trial in collaboration with Roche targeting SARS-COV-2. The company is a pure play developer of therapies for severe viral diseases including vaccines for RNA viruses.
Genius Sports enters data, trading partnership with Golden Nugget Online 08:05 GENI, GNOG Genius Sports (GENI) Etsy price target raised to $265 from $220 at Jefferies 08:04 ETSY Jefferies analyst John Colantuoni raised the firm's price target on Etsy to $265 from $220 and keeps a Buy rating on the shares. While Colantuoni believes that a combination of potential upside to consensus GMS and a 25%+ 3-yr EBITDA CAGR will lead to long-term outperformance, a current near-peak multiple may keep the stock range-bound until year-end when the market starts addressing valuation on 2023 EBITDA, the analyst tells investors in a research note. Cracker Barrel raises quarterly dividend to pre-pandemic level of $1.30 p/share 08:03 CBRL Payable on November 9 to shareholders of record on October 22. This dividend represents a return to the company's pre-pandemic quarterly dividend level. Additionally, the Board of Directors authorized share repurchases up to $100M of the company's outstanding common stock. Central Garden & Pet positioned to meet or exceed estimates, says Monness Crespi 08:01 CENTA Monness Crespi analyst Jim Chartier tells investors in a research note that Millennials will be the largest group of homeowners in the U.S. by 2035, representing a favorable trend for the garden and pet categories. In the near-term, Chartier believes trends in the pet category remain strong and garden sales are solid, and thinks Central Garden & Pet is positioned to meet or exceed expectations in Q4. The analyst made no change to his Buy rating and $59 price target, and thinks risk/reward is very favorable. Draganfly's Vital Intelligence system available in Fobi's Venue Management 07:48 DPRO Draganfly is pleased to announce that its Vital Intelligence Smart Vital system has been integrated into Fobi AI;s Venue Management System for Conferences & Events. The venue management platform will now consist of Draganfly's Smart Vital assessment system, Fobi's Passcreator mobile Wallet passes, proprietary Smart Tap Devices, Smart Scan Pass Validation App and Insight Portal for event analytics. Prior to an event, Fobi allows organizers to prompt guests to complete health screening on their phones. Using the phone's camera, Draganfly's Smart Vital system monitors, with voluntary consent, vital signs which include body temperature, heart rate, breathing rate and blood oxygen content. It does not register any personal data of the individual being screened.
Paycor enhances HCM solution with Immunization Tracker 09:10 PYCR Paycor H Alert-* Sundial Growers(NASDAQ:SNDL)has reacquired more than 10% of the issued outstanding common shares of The Valens Company(OTCQX:VLNCF). On September 17, 2021, Sundial acquired 100K common shares at $3.00/share (the Transaction) for total consideration of $300K. Following the completion of the Transaction, Sundial now owns ~18.7M shares representing ~10.00% of the issued and outstanding common shares on a non-diluted basis as at September 20, 2021. Sundial's average cost base for the common shares, including those acquired in the Transaction, is $2.665/share. This news release is being issued to comply with National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. VLNCF-$1.89<------------
Incredible relative strength by Paycor yesterday... Paycor HCM, Inc. (PYCR)- wasn't this one of the index add stks? Nasdaq 31.49+0.82 (+2.67%) At close: September 20 4:00PM EDT